Loading organizations...
§ Private Profile · Winston-Salem, NC, USA
Develops small molecule therapeutics for substance abuse, targeting cocaine & methamphetamine addiction.
Key people at Encepheal Therapeutics.
Encepheal Therapeutics was founded in 2015 by Omeed Rahimi (Founder) and Aaron Lazarus (Founder).
Based in Winston-Salem, North Carolina, Encepheal Therapeutics is a clinical-stage biotechnology company that develops novel small molecule therapeutics designed to treat severe substance abuse disorders. The organization primarily focuses on creating pharmacological treatments for stimulant addictions, specifically targeting cocaine and methamphetamine dependencies for which there are currently no FDA-approved medications available on the commercial market. Operating with a core team of three employees, the enterprise utilizes atypical allosteric modulators of the dopamine transporter to reduce patient cravings and neurological positive reinforcement without introducing new addictive tendencies during treatment. To advance its proprietary clinical research, the company has secured non-dilutive capital through federal grants while collaborating with recognizable institutional partners including Y Combinator, the National Institute on Drug Abuse, and Wake Forest University. Encepheal Therapeutics was officially founded in 2015 by Aaron Lazarus and Omeed Rahimi.
Key people at Encepheal Therapeutics.
Encepheal Therapeutics was founded in 2015 by Omeed Rahimi (Founder) and Aaron Lazarus (Founder).
EncepHeal Therapeutics is a biotech company developing first-in-class neurotherapeutics aimed at treating substance abuse disorders, with an initial focus on stimulants such as cocaine and methamphetamine. Their products target a significant unmet need by providing effective, non-addictive medications where current treatment options are lacking. EncepHeal serves patients suffering from addiction and mental health disorders, aiming to break the cycle of addiction through advanced pharmacological approaches. The company has demonstrated growth momentum, reaching an estimated $5 million in annual revenue by 2025 and securing funding from notable sources including Y Combinator and the North Carolina Biotechnology Center[1][3][5].
Founded in 2015 by a team of graduate students including CEO Aaron Lazarus, EncepHeal emerged from academic research and startup competitions in Winston-Salem’s Innovation Quarter. The founders licensed a novel class of compounds from the National Institute on Drug Abuse and quickly gained early traction through grants and partnerships with institutions like Wake Forest University and the NIH. This academic-industry collaboration and early funding success helped EncepHeal transition from a research project to a biotech startup focused on developing safe, effective treatments for stimulant addiction[2][4][7].
EncepHeal rides the rising trend of applying advanced neuropharmacology to mental health and addiction, a field gaining urgency amid the opioid crisis and increasing stimulant abuse. The timing is critical as there are currently no FDA-approved treatments for cocaine or methamphetamine addiction, creating a large unmet medical need. Market forces such as growing awareness of addiction’s societal impact, increased funding for mental health innovation, and advances in drug development technologies favor EncepHeal’s growth. By pioneering therapeutics in this niche, EncepHeal influences the broader biotech ecosystem by demonstrating the viability of next-generation neurotherapeutics for substance abuse, potentially inspiring further innovation and investment in this space.
Looking ahead, EncepHeal is positioned to advance its lead compounds through clinical development, aiming for FDA approval and commercialization. Trends shaping their journey include increasing public and governmental focus on addiction treatment, advances in personalized medicine, and expanding biotech innovation hubs like the Innovation Quarter. As EncepHeal scales, its influence may extend beyond stimulant addiction to broader mental health disorders, potentially transforming treatment paradigms. Their success could catalyze more investment in neurotherapeutics and strengthen the biotech startup ecosystem in Winston-Salem and beyond, fulfilling their mission to break the cycle of addiction with novel, effective medicines.
